Statins in lipid-lowering therapy

Acta Cardiologica Sinica

Volumn 19, Issue 1, 2003, Pages 1-11

  Zhao, Hai Lu ^a   Thomas, G Neil ^a   Leung, Wilson Y S ^a   Tomlinson, Brian ^a   Hsieh, Ming Hsiung ^b   Chan, Paul ^b  

^a CHINESE UNIVERSITY OF HONG KONG   (Hong Kong)

^b TAIPEI MEDICAL UNIVERSITY   (Taiwan)

Author keywords

Coronary heart disease; Effectiveness; Safety; Statin

Indexed keywords

3 HYDROXY 3 METHYLGLUTARYL COENZYME A; ATORVASTATIN; CERIVASTATIN; FLUINDOSTATIN; MEVINOLIN; PRAVASTATIN; SIMVASTATIN; STATIN;

ABDOMINAL PAIN; ASTHENIA; CANCER; CHEMOPROPHYLAXIS; CLINICAL TRIAL; CONSTIPATION; COST EFFECTIVENESS ANALYSIS; DIABETES MELLITUS; DRUG RESEARCH; DRUG SAFETY; DYSPEPSIA; ENDOTHELIUM; FATIGUE; FLATULENCE; GASTROINTESTINAL SYMPTOM; HEADACHE; HUMAN; ISCHEMIC HEART DISEASE; LIVER TOXICITY; META ANALYSIS; MORALITY; MYOPATHY; NAUSEA; PHYSICIAN; PRIMARY MEDICAL CARE; RASH; REVIEW; SLEEP DISORDER; STROKE; VERTIGO;

EID: 0038612802     PISSN: 10116842     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (47)

1. Stamler J, Wentworth D, Neaton JD. Is relationship between serum cholesterol and risk of premature death from coronary heart disease continuous and graded? Findings in 356,222 primary screenees of the Multiple Risk Factor Intervention Trial (MRFIT). JAMA 1986;256:2823-8.
2. Wakugami K, Iseki K, Kimura Y, et al. Relationship between serum cholesterol and the risk of acute myocardial infarction in a screened cohort in Okinawa, Japan. Jpn Circ J 1998;62:7-14.
3. Castelli WP. Epidemiology of coronary heart disease: the Framingham study. Am J Med 1984;76:4-12.
4. LaRosa JC, Hunninghake D, Bush D, et al. The cholesterol facts: a summary of the evidence relating dietary fats, serum cholesterol, and coronary heart disease. A joint statement by the American Heart Association and the National Heart, Lung, and Blood Institute. The Task Force on Cholesterol Issues, American Heart Association. Circulation 1990;81:1721-33.
5. Chen Z, Peto R, Collins R, et al. Serum cholesterol concentration and coronary heart disease in population with low cholesterol concentrations. BMJ 1991;303:276-82.
6. Verschuren WM, Jacobs DR, Bloemberg BP, et al. Serum total cholesterol and long-term coronary heart disease mortality in different cultures: twenty-five-year follow-up of the seven countries study. JAMA 1995;274:131-6.
7. Law MR, Wald NJ, Thompson SG. By how much and how quickly does reduction in serum cholesterol concentration lower risk of ischaemic heart disease? BMJ 1994;308:367-72.
8. Law MR, Wald NJ. An ecological study of serum cholesterol and ischaemic heart disease between 1950 and 1990. Eur J Clin Nutr 1994;48:305-25.
9. Shepherd J, Cobbe SM, Ford I, et al. Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. West of Scotland Coronary Prevention Study Group. N Engl J Med 1995;333:1301-7.
10. Hebert PR, Gaziano JM, Chan KS, et al. Cholesterol lowering with statin drugs, risk of stroke, and total mortality: an overview of randomized trials. JAMA 1997;278:313-21.
11. Design, rationale, and baseline characteristics of the Prospective Pravastatin Pooling (PPP) project - a combined analysis of three large-scale randomized trials: Long-term Intervention with Pravastatin in Ischemic Disease (LIPID), Cholesterol and Recurrent Events (CARE), and West of Scotland Coronary Prevention Study (WOSCOPS). Am J Cardiol 1995;76:899-905.
12. LaRosa JC, He J, Vupputuri S. Effect of statins on risk of coronary disease: a meta-analysis of randomized controlled trials. JAMA 1999;282:2340-6.
13. MRC/BHF Heart Protection Study of cholesterol-lowering therapy and of antioxidant vitamin supplementation in a wide range of patients at increased risk of coronary heart disease death: early safety and efficacy experience. Eur Heart J 1999;20: 725-41.
14. Ahsan CH, Shah A, Ezekowitz M. Acute statin treatment in reducing risk after acute coronary syndrome: the MIRACL (Myocardial Ischemia Reduction with Aggressive Cholesterol Lowering) Trial. Curr Opin Cardiol 2001;16:390-3.
15. Patrick WJ, de Feyter P, Macaya C, et al. Fluvastatin for prevention of cardiac events following successful first percutaneous coronary intervention. JAMA 2002;287:3212-22.
16. Lemaitre RN, Psaty BM, Heckbert SR, et al. Therapy with hydroxymethylglutaryl coenzyme a reductase inhibitors (statins) and associated risk of incident cardiovascular events in older adults. Arch Intern Med 2002;1395-400.
17. Stenestrand U, Wallentin L. Early statin treatment following acute myocardial infarction and 1-year survival. JAMA 2001; 285:430-6.
18. Penny WF, Ben-Yehuda O, Kuroe K, et al. Improvement of coronary artery endothelial dysfunction: with lipid-lowering therapy: heterogeneity of segmental response and correlation with plasma-oxidized low density lipoprotein. J Am Coll Cardiol 2001;37:766-74.
19. Bucher HC, Griffith LE, Guyatt GH. Systematic review on the risk and benefit of different cholesterol-lowering interventions. A rterioscler Thromb Vasc Biol 1999;19:187-95.
20. Andrews TC, Ballantyne CM, Hsia JA, et al. Achieving and maintaining National Cholesterol Education Program low-density lipoprotein cholesterol goals with five statins. Am J Med 2001;111:185-91.
21. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). Lancet 1994;344:1383-9.
22. Bjerre LM, LeLorier J. Do statins cause cancer? A meta-analysis of large randomized clinical trials. Am J Med 2001;110:716-23.
23. Tomlinson B, Chan P, Lan W. How well tolerated are lipid- lowering drugs? Drugs Aging 2001;18:665-83.
24. Heart Protection Study Collaboration Group. MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20536 high-risk individuals: a randomized placebo-controlled trial. Lancet 2002;360:7-22
25. Gaist D, Rodriguez LA, Huerta C, et al. Lipid-lowering drugs and risk of myopathy: a population-based follow-up study. Epidemiology 2001;12:565-9.
26. Omar MA, Wilson JP, Cox TS. Rhabdomyolysis and HMG-CoA reductase inhibitors. Ann Pharmacother 2001;35:1096-107.
27. Igel M, Sudhop T, von Bergmann K. Metabolism and drug interactions of 3-hydroxy-3-methylglutaryl coenzyme A-reductase inhibitors (statins). Eur J Clin Pharmacol 2001;57:357-64.
28. The LIPID Study Group. Long-term effectiveness and safety of pravastatin in 9014 patients with coronary heart disease and average cholesterol concentrations: the LIPID trial follow-up. Lancet 2002;359:1379-87.
29. Davidson MH. Treatment of the elderly with 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors: focus on drug interactions. J Cardiovasc Pharmacol Ther 2001;6:219-29.
30. Pharoah PD, Hollingworth W. Cost effectiveness of lowering cholesterol concentration with statins in patients with and without pre-existing coronary heart disease: life table method applied to health authority population. BMJ 1996;312:1443-8.
31. Hay JW, Yu WM, Ashraf T. Pharmacoeconomics of lipid- lowering agents for primary and secondary prevention of coronary artery disease. Pharmacoeconomics 1999;15:47-74.
32. Szucs TD. Pharmaco-economic aspects of lipid-lowering therapy: Is it worth the price? Eur Heart J 1998;19(suppl M):22-8.
33. Ganz DA, Kuntz KM, Jacobson GA, et al. Cost-effectiveness of 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor therapy in older patients with myocardial infarction. Ann Intern Med 2000;132:780-7.
34. Reckless JP. Cost-effectiveness of statins. Curr Opin Lipidol 2000;11:351-6.
35. Thorvik E, Aursnes I, Kristiansen IS, et al. Cost effectiveness of cholesterol-lowering drugs: a review of the evidence. Wien Klin Wochenschr 1996;108:234-43.
36. Pickin DM, McCabe CJ, Ramsay LE, et al. Cost effectiveness of HMG-CoA reductase inhibitor (statin) treatment related to the risk of coronary heart disease and cost of drug treatment. Heart 1999;82:325-32.
37. van Hout BA, Simoons ML. Cost-effectiveness of HMG coenzyme reductase inhibitors: Whom to treat? Eur Heart J 2001;22:751-61.
38. Chong PH, Seeger JD, Franklin C. Clinically relevant differences between the statins: implications for therapeutic selection, Am J Med 2001;111:390-400.
39. Perreault S, Levinton C, Le Lorier J. Efficacy and cost of HMG-CoA reductase inhibitors in the treatment of patients with primary hyperlipidemia. Can J Clin Pharmacol 2000;7:144-54.
40. Huse DM, Russell MW, Miller JD, et al. Cost-effectiveness of statins. Am J Cardiol 1998;82:1357-63.
41. Russell MW, Huse DM, Miller JD, et al. Cost effectiveness of HMG-CoA reductase inhibition in Canada. Can J Clin Pharmacol 2001;8:9-16.
42. Ballesteros LC, Fernandez San Martin MI, Sanz Cuesta T, et al. The cost of inadequate prescriptions for hypolipidaemic drugs. VICAF Group. Pharmacoeconomics 2001;19:513-22.
43. Jacobson TA, Schein JR, Williamson A, et al. Maximizing the cost-effectiveness of lipid-lowering therapy. Arch Intern Med 1998;158:1977-89.
44. Hooper L, Summerbell CD, Higgins JP, et al. Reduced or modified dietary fat for preventing cardiovascular disease (Cochrane Review). Cochrane Database Syst Rev 2001;3.
45. Downs JR, Clearfield M, Weis S, et al. Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: results of AFCAPS/TexCAPS. Air Force/Texas Coronary Atherosclerosis Prevention Study. JAMA 1998;279:1615-22.
46. Sacks FM, Pfeffer MA, Moye LA, et al. The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol and Recurrent Events Trial investigators. N Engl J Med 1996;335:1001-9.
47. Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels. The Long-Term Intervention with Pravastatin in Ischaemic Disease (LIPID) study Group. N Engl J Med 1998;339:1349-57.